Thiruvananthapuram: The controversy surrounding the Kerala government’s move to change the medication provided to children suffering from Spinal Muscular Atrophy (SMA) has intensified following fresh revelations. Visuals showing representatives of pharmaceutical company Natco visiting the minister’s office for a meeting have surfaced, putting the Health Department under renewed scrutiny. The developments have raised questions about whether the pharmaceutical company had any influence over the decision to replace the existing medication.
According to the information that has emerged, representatives of Natco visited the minister’s office and participated in discussions. Dr. I. Riyas, Superintendent of the Sree Avittom Thirunal (SAT) Hospital in Thiruvananthapuram, was reportedly present during the meeting.
The Health Department has confirmed that the meeting took place. However, officials maintain that the discussions were unrelated to the proposed change in SMA medication. According to the department, the company representatives had approached the minister’s office regarding matters connected with Corporate Social Responsibility (CSR) initiatives.
Nevertheless, the timing of the meeting has triggered questions, particularly because it reportedly occurred while the government was proceeding with plans to introduce a different medication for children undergoing SMA treatment.
Questions are now being raised about the actual purpose of the meeting, whether company representatives played any role in the drug selection process, and whether the government obtained recommendations from an expert medical committee before deciding to change the medication.
However, the meeting itself does not establish that the company influenced the government’s decision.
The controversy has taken another turn following the emergence of a letter reportedly submitted to the minister by families of children affected by SMA.
The letter allegedly expressed serious concerns about the safety, effectiveness, and reliability of the proposed new medication.
The development has cast doubt on the minister’s earlier statement that no complaints had been received from SMA patients or their families regarding the new drug.
According to information now emerging, the letter was submitted before the authorities proceeded with the decision to change the medication and place an order for the new drug.
This has prompted questions about whether the government was already aware of the families’ concerns and whether those concerns were adequately examined before the procurement decision was made.
The minister had previously maintained that no complaints had been received and that any concerns brought to the government’s attention would be examined.
However, the emergence of what is described as documentary evidence of an earlier complaint has renewed scrutiny of that explanation.
The date on which the letter was submitted, when it was officially received by the minister’s office, and what subsequent action was taken are now crucial issues requiring clarification.
Children affected by SMA had previously been receiving medication through SAT Hospital in Thiruvananthapuram.
The government’s decision to introduce a different drug has generated anxiety among parents, who say they have not received sufficient information regarding its safety and clinical effectiveness.
The Health Department has maintained that there is no reason for concern merely because the proposed medication is manufactured in India.
However, parents argue that the country of manufacture alone cannot determine a medicine’s safety or effectiveness.
They insist that any decision to introduce a new medication must be supported by reliable clinical evidence, quality assessments, regulatory approvals, and recommendations from qualified medical experts.
Families are particularly concerned about the possible consequences of changing treatment for children who are already receiving medication and whose medical conditions require continuous monitoring.
They have demanded that the government make available relevant scientific studies, clinical evaluation reports, and safety data before implementing the proposed change.
Parents also want clarity on whether the new medication has been adequately evaluated for children currently undergoing treatment and whether switching drugs could affect their health or treatment outcomes.
Spinal Muscular Atrophy is a rare genetic disorder that affects motor neurons, the nerve cells responsible for controlling voluntary muscle movements.
The disease causes progressive muscle weakness and can significantly affect a child’s ability to sit, stand, walk, and perform everyday activities.
In severe cases, SMA can also interfere with breathing and swallowing, making timely diagnosis, appropriate medication, and continuous medical supervision essential.
Several specialized treatments are available to manage SMA, depending on the type and severity of the condition.
These treatments aim to slow disease progression, preserve muscle function, and improve patients’ quality of life.
Because SMA is a serious condition that often requires long-term treatment, the quality, effectiveness, and safety of medication are particularly important.
Medical decisions involving a change from one treatment to another generally require careful clinical evaluation, appropriate monitoring, and consideration of the individual patient’s condition.
Parents argue that such decisions should be based on established medical evidence rather than administrative or financial considerations alone.
The latest developments have intensified demands for greater transparency in the government’s decision-making process concerning SMA medication.
Questions have been raised about the criteria used to select the proposed replacement drug and whether the authorities conducted a comprehensive assessment before moving forward with procurement.
Those seeking clarification have called for the disclosure of details concerning the meeting with Natco representatives, recommendations made by medical experts, the regulatory status of the proposed medication, and documents relating to its safety and effectiveness.
Another major question is whether the decision to replace the existing drug was influenced by cost considerations, availability, or demonstrated therapeutic benefits.
While efforts to make expensive medicines more affordable and accessible are widely welcomed, parents insist that cost reduction must not come at the expense of patient safety.
They argue that the government has a responsibility to ensure that any medication supplied to children with SMA meets appropriate medical and regulatory standards.
The controversy has also highlighted the importance of maintaining public confidence in government healthcare procurement, particularly when decisions involve treatment for children with rare and potentially life-threatening diseases.
Families of SMA patients have strongly urged the government not to expose their children to medication that has not undergone the necessary scientific and safety evaluations.
They maintain that children suffering from serious genetic disorders should not be subjected to avoidable risks arising from changes in treatment protocols.
Parents are seeking clear answers about the proposed drug’s approval status, available clinical evidence, possible side effects, and precautions required when switching from the existing treatment.
They have also emphasized that any change should take place only under the supervision of qualified specialists and after an individualized assessment of each child’s medical condition.
At the same time, whether the proposed medication is experimental or an approved treatment remains a matter requiring verification. The parents’ concerns alone do not establish that the new drug is unsafe or ineffective.
Families have called on the Health Department to engage directly with affected parents, address their concerns, and ensure that decisions are guided primarily by the medical needs and long-term well-being of children.
With visuals of the meeting involving Natco representatives and the reportedly submitted complaint letter now emerging, the SMA drug controversy has entered a new phase.
The Health Department faces growing demands to explain the circumstances surrounding the meeting, the basis for selecting the new medication, and the sequence of events leading to the procurement decision.
The department’s response to questions about the reported complaint letter will also be significant in determining whether concerns raised by families were properly acknowledged and examined.
The central issue is not simply whether a pharmaceutical company met government officials, but whether the entire process of selecting and introducing medication for vulnerable children was conducted transparently, independently, and in accordance with accepted medical standards.
The government is now expected to provide a comprehensive explanation addressing the concerns surrounding the proposed drug change and the circumstances that have brought the Health Department under renewed scrutiny.
